A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults

Summary

The purpose of this study is to examine the safety and tolerability of HFB30132A when it is given by single intravenous infusion in Chinese healthy participants.

Timeline

Start

2021-05-09

Primary completion

2022-02-22

Completion

2022-02-22

Publications

• Chen Y, Li S, Hedrich W, Wu X, Li S, Qiu C, Lin K, Bian X, He J, Zhou H, Adrian F, Schweizer L, Zhang J. Population pharmacokinetics and pharmacodynamics of HFB30132A, a monoclonal antibody against SARS-CoV-2, in healthy Chinese and US subjects. Int J Antimicrob Agents. 2025 Mar;65(3):107439. doi: 10.1016/j.ijantimicag.2024.107439. Epub 2025 Jan 9.
• Li S, Wu X, Li N, Cao G, Wang J, Chen Y, Li S, He J, Wu J, Yang H, Lin K, Qiu C, Liu A, Zhou H, Adrian F, Schweizer L, Zhang W, Gu J, Zhang J. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study. Front Pharmacol. 2023 May 23;14:1117293. doi: 10.3389/fphar.2023.1117293. eCollection 2023.

Drugs

Indications

No indication recorded.